Continuously functioning artificial nephron system: The promise of nanotechnology

Nearly 900,000 patients worldwide have end‐stage renal disease and require dialysis or kidney transplantation. Despite the availability of these forms of renal replacement therapy for nearly four decades, mortality and morbidity are high and patients often have a poor quality of life. We have developed a human nephron filter (HNF) utilizing nanotechnology that would eventually make feasible a continuously functioning, wearable or implantable artificial kidney. The device consists of two membranes operating in series within one device cartridge. The first membrane mimics the function of the glomerulus, using convective transport to generate a plasma ultrafiltrate containing all solutes approaching the molecular weight of albumin. The second membrane mimics the function of the renal tubules, selectively reclaiming designated solutes to maintain body homeostasis. No dialysis solution is used in this device. The HNF has been computer‐modeled, and operating 12 hr per day, 7 days per week the HNF provides the equivalent of 30 mL/min glomerular filtration rate (compared to half that amount for conventional thrice‐weekly hemodialysis). Animal studies should begin in the next 1 to 2 years, and clinical trials would then follow 1 to 2 years subsequent. The HNF system, by eliminating dialysate and utilizing a novel membrane system created through applied nanotechnology, represents a breakthrough in renal replacement therapy based on the functioning of native kidneys. The enhanced solute removal and wearable design should substantially improve patient outcomes and quality of life.

[1]  D. Zimmerman Hemofiltration as a treatment for end‐stage renal disease , 2004, Hemodialysis international. International Symposium on Home Hemodialysis.

[2]  A. Pierratos Daily (quotidian) nocturnal home hemodialysis: Nine years later , 2004, Hemodialysis international. International Symposium on Home Hemodialysis.

[3]  J. Winchester,et al.  Middle molecules and small-molecular-weight proteins in ESRD: properties and strategies for their removal. , 2003, Advances in renal replacement therapy.

[4]  Kenichi Iga,et al.  Introduction to Nanotechnology , 2002, Fluorescent Nanodiamonds.

[5]  T. Depner Daily hemodialysis efficiency: an analysis of solute kinetics. , 2001, Advances in renal replacement therapy.

[6]  R. Lindsay,et al.  Hemeral (daily) hemodialysis. , 2001, Advances in renal replacement therapy.

[7]  Claudio Ronco,et al.  Does Nanotechnology Apply to Dialysis? , 2001, Blood Purification.

[8]  W. Clark Quantitative Characterization of Hemodialyzer Solute and Water Transport , 2001, Seminars in dialysis.

[9]  T. Petitclerc,et al.  Festschrift for Professor Claude Jacobs. Recent developments in conductivity monitoring of haemodialysis session. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  P. Fagette Hemodialysis 1912-1945: no medical technology before its time: part II. , 1999, ASAIO journal (1992).

[11]  A. Nissenson,et al.  ESRD modality selection into the 21st century: the importance of non medical factors. , 1997, ASAIO journal.

[12]  N. Hoenich,et al.  Hemodialyzer performance: a review of the trends over the past two decades. , 1995, Artificial organs.

[13]  A. Nissenson,et al.  Non-medical factors that impact on ESRD modality selection. , 1993, Kidney international. Supplement.

[14]  W. Clark What Clinically Important Advances in Understanding and Improving Dialyzer Function Have Occurred Recently? , 2001, Seminars in dialysis.

[15]  P. Fagette Hemodialysis 1912-1945: no medical technology: before its time: part I. , 1999, ASAIO journal (1992).

[16]  C. Ronco,et al.  The role of technology in hemodialysis. , 1999, Journal of nephrology.

[17]  C. Kjellstrand,et al.  The "unphysiology" of dialysis: a major cause of dialysis side effects? , 1975, Kidney international. Supplement.